{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:52:16Z","timestamp":1789487536890,"version":"build-2803163510"},"reference-count":140,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:29:35Z","timestamp":1784125775000},"page":"1232-1254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin Withdrawal in Patients With Coronary Artery Disease"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5192-886X","authenticated-orcid":false,"given":"Jurrien ten","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa H.","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-891X","authenticated-orcid":false,"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2026.06.003_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-026-01249-z","article-title":"Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies","author":"Galli","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/eurheartj\/ehaf718","article-title":"Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?","volume":"47","author":"Galli","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/eurheartj\/ehae324","article-title":"Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease","volume":"45","author":"Patrono","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib6","first-page":"804","article-title":"Trade-off of myocardial infarction vs bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state of the art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib9","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14740338.2021.1850691","article-title":"Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions","volume":"20","author":"Galli","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2026.06.003_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/eurheartj\/ehaf473","article-title":"Sex differences in dual antiplatelet therapy deescalation strategies after percutaneous coronary intervention: a network meta-analysis","volume":"47","author":"Occhipinti","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib19","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ehjcvp\/pvaf034","article-title":"Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy","volume":"11","author":"Galli","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ehjcvp\/pvae057","article-title":"P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ehjcvp\/pvae036","article-title":"Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and pharmacology of the platelet P2Y12 receptor","volume":"12","author":"Storey","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2026.06.003_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11239-024-03022-w","article-title":"Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital","volume":"58","author":"Galli","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2026.06.003_bib29","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.jcin.2024.08.027","article-title":"International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update","volume":"17","author":"Angiolillo","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","article-title":"Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations","volume":"14","author":"Galli","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.06.003_bib32","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib34","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib35","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib36","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jacc.2026.06.003_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.06.003_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016495","article-title":"Pharmacodynamic comparison of ticagrelor monotherapy versus ticagrelor and aspirin in patients after percutaneous coronary intervention: the TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) randomized controlled trial","volume":"9","author":"Johnson","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.06.003_bib41","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after PCI: the TWILIGHT Platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09537104.2020.1863937","article-title":"Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy","volume":"33","author":"Hennigan","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jacc.2026.06.003_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib44","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.jacc.2024.05.084","article-title":"Aspirin hypersensitivity in patients with atherosclerotic cardiovascular disease","volume":"84","author":"Galli","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib45","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib47","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.003_bib48","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib49","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib51","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib52","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib53","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib54","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/eurheartj\/ehaf070","article-title":"Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months","volume":"46","author":"Byrne","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jacc.2024.06.038","article-title":"Genotype-guided antiplatelet therapy: JACC review topic of the week","volume":"84","author":"van den Broek","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib56","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib58","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jcin.2025.11.029","article-title":"Genotype-guided vs conventional oral P2Y12 inhibitors in acute coronary syndrome: a combined analysis of TAILOR-PCI and Popular Genetics","volume":"19","author":"Galli","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009434","article-title":"Clopidogrel versus ticagrelor or prasugrel after primary percutaneous coronary intervention according to CYP2C19 genotype","volume":"14","author":"Claassens","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib60","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided deescalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib62","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib63","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","author":"Cao","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/ijms26031136","article-title":"Combining colchicine and antiplatelet therapy to tackle atherothrombosis: a paradigm in transition?","volume":"26","author":"Giordano","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2026.06.003_bib66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ehjcvp\/pvae019","article-title":"De-escalation versus shortening of dual antiplatelet therapy","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib67","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, noninferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib68","article-title":"Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS\/PCI: a critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacc.2026.06.003_bib69","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib70","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after pci in acute coronary syndromes","volume":"393","author":"Guimaraes","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib71","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib73","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacasi.2025.04.010","article-title":"Position statement on antiplatelet therapy for East Asians with coronary artery disease: 2025 update","volume":"5","author":"Gong","year":"2025","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacc.2026.06.003_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacasi.2021.12.005","article-title":"Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations","volume":"2","author":"Kwon","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacc.2026.06.003_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehag351","article-title":"Aspirin vs clopidogrel in chronic coronary syndromes: a meta-analysis of ethnic differences","author":"Laudani","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf1050","article-title":"Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial","author":"Tavares","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacc.2025.10.058","article-title":"Potent P2Y12 inhibitor monotherapy vs DAPT AFTER PCI in patients with and without STEMI: the NEO-MINDSET substudy","volume":"87","author":"Tavares","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib78","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.003_bib79","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.003_bib80","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0877","article-title":"P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after deployment of a drug-eluting stent: the SHARE randomized clinical trial","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2026.06.003_bib82","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0140-6736(25)01571-5","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial","volume":"406","author":"Kang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib83","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib84","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib85","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib86","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.003_bib87","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib88","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib89","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction","volume":"393","author":"Tarantini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib90","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.4244\/EIJ-D-25-00331","article-title":"One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial","volume":"21","author":"Jang","year":"2025","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.06.003_bib91","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ehjcvp\/pvaf045","article-title":"Entering a new era of antiplatelet therapy: the 4D-ACS trial","volume":"11","author":"Laudani","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib92","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"O\u2019Donoghue","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very short vs long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials","volume":"7","author":"Benenati","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.06.003_bib94","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41569-023-00953-4","article-title":"Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction","volume":"21","author":"Galli","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib96","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib97","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM Extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib98","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/CIRCULATIONAHA.122.063004","article-title":"Long-term P2Y12 inhibitor or aspirin as single antiplatelet therapy in patients with previous percutaneous coronary intervention","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"issue":"10486","key":"10.1016\/j.jacc.2026.06.003_bib99","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib100","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/eurheartj\/ehaf290","article-title":"Weekly journal scan: Is a SMART-CHOICE of clopidogrel monotherapy after coronary stenting supported by adequate evidence?","volume":"46","author":"Galli","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10508","key":"10.1016\/j.jacc.2026.06.003_bib102","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib103","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.06.003_bib104","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial","volume":"9","author":"Li","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41569-023-00857-3","article-title":"The bidirectional association between atrial fibrillation and myocardial infarction","volume":"20","author":"Frederiksen","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib106","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2018.03.018","article-title":"Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: \u201cOLTAT registry.\u201d","volume":"264","author":"Fischer","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib108","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib109","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2020-318750","article-title":"Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation","volume":"108","author":"Choi","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2026.06.003_bib110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2023.2291865","article-title":"Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management","volume":"22","author":"Laudani","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2026.06.003_bib111","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib112","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib113","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib114","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist\u2013based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.06.003_bib115","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib116","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective\u20142021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib117","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib118","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017212","article-title":"Safety and efficacy of double antithrombotic therapy with non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.06.003_bib119","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.06.003_bib120","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2026.06.003_bib121","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.jacc.2020.01.054","article-title":"Stent thrombosis with dual antithrombotic therapy in atrial fibrillation\u2013ACS\/PCI trials","volume":"75","author":"Galli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib122","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib123","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.06.003_bib124","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jcin.2024.03.027","article-title":"P2Y12 inhibition in patients requiring oral anticoagulation after percutaneous coronary intervention: the SWAP-AC-2 study","volume":"17","author":"Ortega-Paz","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa2512091","article-title":"Therapy for atrial fibrillation in patients with drug-eluting stents","volume":"394","author":"Lee","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib126","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib127","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib128","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib129","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5905022","article-title":"Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease","volume":"2022","author":"Fukamachi","year":"2022","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib130","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib131","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jcin.2026.03.020","article-title":"Oral anticoagulation with or without antiplatelet therapy in chronic coronary syndrome: a meta-analysis of randomized trials","volume":"19","author":"Galli","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.06.003_bib132","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.01.026","article-title":"Anticoagulation alone or with antiaggregation in patients with coronary artery disease: meta-analysis of randomized trials","author":"Gargiulo","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib134","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.124.069012","article-title":"Demystifying the contemporary role of 12-month dual antiplatelet therapy after acute coronary syndrome","volume":"150","author":"Valgimigli","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.003_bib135","article-title":"Managing bleeds on anticoagulant therapy: a practical guide for clinicians","author":"Galli","year":"2026","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2026.06.003_bib136","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib137","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jamacardio.2025.5057","article-title":"Ticagrelor vs prasugrel in patients with diabetes and multivessel coronary artery disease: the TUXEDO-2 randomized clinical trial","volume":"11","author":"Bangalore","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.003_bib138","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib139","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.06.003_bib140","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(24)00282-4","article-title":"Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial","volume":"403","author":"Li","year":"2024","journal-title":"Lancet"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:46:46Z","timestamp":1789483606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726067690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":140,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726067690"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.003","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin Withdrawal in Patients With Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}